Brief: Fortress Biotech And Cyprium Therapeutics Announce An Update On The NDA For Cutx-101
01/10/2025 14:54
Oct 1 (Reuters) - Fortress Biotech Inc FBIO.O: FORTRESS BIOTECH AND CYPRIUM THERAPEUTICS ANNOUNCE AN UPDATE ON THE NDA FOR CUTX-101 FORTRESS BIOTECH INC - FDA ISSUES COMPLETE RESPONSE LETTER FOR CUTX-101 NDA FORTRESS BIOTECH INC - CRL NOTES CGMP DEFICIENCIES AT CUTX-101 MANUFACTURING FACILITY FORTRESS BIOTECH INC - SENTYNL TO ADDRESS FDA CONCERNS AND PURSUE RESUBMISSION FORTRESS BIOTECH INC - CYPRIUM ELIGIBLE FOR PRV, ROYALTIES, AND $129 MILLION MILESTONES Source text: ID:nGNX8kv4hB Further company coverage: FBIO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fortress Biotech
See all newsFortress Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Fortress Biotech Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Fortress Biotech And Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
Fortress Biotech Q1 net income jumps on PRV sale
Brief: Journey Medical Corporation Secures Contract With Third Major Gpo For Emrosi